Very early diagnosis of chest pain by point-of-care testing: comparison of the diagnostic efficiency of a panel of cardiac biomarkers compared with troponin measurement alone in the RATPAC trial

Heart ◽  
2011 ◽  
Vol 98 (4) ◽  
pp. 312-318 ◽  
Author(s):  
Paul Collinson ◽  
Steve Goodacre ◽  
David Gaze ◽  
Alasdair Gray
Keyword(s):  
Chest Pain ◽  
Early Diagnosis ◽  
Point Of Care ◽  
Cardiac Biomarkers ◽  
Diagnostic Efficiency ◽  
Point Of Care Testing

Assessing the Performance of a Novel Point-of-Care Qualitative Assay for Early Diagnosis of Acute Coronary Syndrome

Cardiology ◽  
2020 ◽  
pp. 1-8
Author(s):  
Ronny Alcalai ◽  
Boris Varshisky ◽  
Ahmad Marhig ◽  
David Leibowitz ◽  
Larissa Kogan-Boguslavsky ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Chest Pain ◽  
Diagnostic Accuracy ◽  
Diagnostic Performance ◽  
Troponin I ◽  
Point Of Care ◽  
Final Diagnosis ◽  
Cardiac Biomarkers ◽  
Fatty Acid Binding ◽  
Coronary Syndrome

<b><i>Background:</i></b> Early and accurate diagnosis of acute coronary syndrome (ACS) is essential for initiating lifesaving interventions. In this article, the diagnostic performance of a novel point-of-care rapid assay (SensAheart<sup>©</sup>) is analyzed. This assay qualitatively determines the presence of 2 cardiac biomarkers troponin I and heart-type fatty acid-binding protein that are present soon after onset of myocardial injury. <b><i>Methods:</i></b> We conducted a prospective observational study of consecutive patients who presented to the emergency department with typical chest pain. Simultaneous high-sensitive cardiac troponin T (hs-cTnT) and SensAheart testing was performed upon hospital admission. Diagnostic accuracy was computed using SensAheart or hs-cTnT levels versus the final diagnosis defined as positive/negative. <b><i>Results:</i></b> Of 225 patients analyzed, a final diagnosis of ACS was established in 138 patients, 87 individuals diagnosed with nonischemic chest pain. In the overall population, as compared to hs-cTnT, the sensitivity of the initial SensAheart assay was significantly higher (80.4 vs. 63.8%, <i>p</i> = 0.002) whereas specificity was lower (78.6 vs. 95.4%, <i>p</i> = 0.036). The overall diagnostic accuracy of SensAheart assay was similar to the hs-cTnT (82.7% compared to 76.0%, <i>p</i> = 0.08). <b><i>Conclusions:</i></b> Upon first medical contact, the novel point-of-care rapid SensAheart assay shows a diagnostic performance similar to hs-cTnT. The combination of 2 cardiac biomarkers in the same kit allows for very early detection of myocardial damage. The SensAheart assay is a reliable and practical tool for ruling-in the diagnosis of ACS.

Cardiac biomarkers and the case for point-of-care testing

2009 ◽  
Vol 42 (7-8) ◽  
pp. 549-561 ◽  
Author(s):  
Barry McDonnell ◽  
Stephen Hearty ◽  
Paul Leonard ◽  
Richard O'Kennedy
Keyword(s):  
Point Of Care ◽  
Cardiac Biomarkers ◽  
Point Of Care Testing

scholarly journals Point-of-care testing in the early diagnosis of acute pesticide intoxication: The example of paraquat

2018 ◽  
Vol 12 (1) ◽  
pp. 011501 ◽  
Author(s):  
Ting-Yen Wei ◽  
Tzung-Hai Yen ◽  
Chao-Min Cheng
Keyword(s):  
Early Diagnosis ◽  
Point Of Care ◽  
Point Of Care Testing

scholarly journals Cardiac biomarkers by point-of-care testing – back to the future?

2020 ◽  
Vol 44 (2) ◽  
pp. 89-95 ◽  
Author(s):  
Paul Collinson
Keyword(s):  
Decision Making ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Troponin T ◽  
Point Of Care ◽  
Patient Flow ◽  
High Sensitivity ◽  
Cardiac Biomarkers ◽  
Point Of Care Testing ◽  
Diagnostic Laboratory

AbstractThe measurement of the cardiac troponins (cTn), cardiac troponin T (cTnT) and cardiac troponin I (cTnI) are integral to the management of patients with suspected acute coronary syndromes (ACS). Patients without clear electrocardiographic evidence of myocardial infarction require measurement of cTnT or cTnI. It therefore follows that a rapid turnaround time (TAT) combined with the immediacy of results return which is achieved by point-of-care testing (POCT) offers a substantial clinical benefit. Rapid results return plus immediate decision-making should translate into improved patient flow and improved therapeutic decision-making. The development of high sensitivity troponin assays offer significant clinical advantages. Diagnostic algorithms have been devised utilising very low cut-offs at first presentation and rapid sequential measurements based on admission and 3 h sampling, most recently with admission and 1 h sampling. Such troponin algorithms would be even more ideally suited to point-of-care testing as the TAT achieved by the diagnostic laboratory of typically 60 min corresponds to the sampling interval required by the clinician using the algorithm. However, the limits of detection and analytical imprecision required to utilise these algorithms is not yet met by any easy-to-use POCT systems.

Sign in / Sign up

Export Citation Format

Share Document